Literature DB >> 33970438

Structural feature of TRAFs, their related human diseases and therapeutic intervention.

Hyun Ho Park1,2.   

Abstract

Several studies have been conducted over the years to unravel the structural information on the receptors that bind to tumor necrosis factor receptor-associated factor (TRAF) and the driving forces for the TRAF/receptor complex. In addition, studies have also been performed to highlight the influence of TRAF malfunctioning and mutations on the development of human disease. However, a holistic study that systematically summarizes the available information and the existing clinical trends towards development of the TRAF-targeting drugs has not been conducted to date. Herein, I reviewed existing research that focused on the structural information of various receptors recognized by the different members of the TRAF family. I also reviewed studies on the different human diseases that occur due to TRAF malfunctioning or mutations as well as the clinical trials undertaken to treat TRAF-associated diseases.

Entities:  

Keywords:  Innate immunity; Structure-based drug design; TRAF domain; TRAF family; TRAF-associated diseases

Mesh:

Substances:

Year:  2021        PMID: 33970438     DOI: 10.1007/s12272-021-01330-w

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  101 in total

Review 1.  Tumor necrosis factor receptor-associated factors (TRAFs)--a family of adapter proteins that regulates life and death.

Authors:  R H Arch; R W Gedrich; C B Thompson
Journal:  Genes Dev       Date:  1998-09-15       Impact factor: 11.361

2.  The signaling adaptor TRAF1 negatively regulates Toll-like receptor signaling and this underlies its role in rheumatic disease.

Authors:  Ali A Abdul-Sater; Maria I Edilova; Derek L Clouthier; Achire Mbanwi; Elisabeth Kremmer; Tania H Watts
Journal:  Nat Immunol       Date:  2016-11-28       Impact factor: 25.606

Review 3.  TRAF family molecules in T cells: Multiple receptors and functions.

Authors:  Tina Arkee; Gail A Bishop
Journal:  J Leukoc Biol       Date:  2019-11-21       Impact factor: 4.962

4.  Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation.

Authors:  Jeganathan Ramesh Babu; Thangiah Geetha; Marie W Wooten
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

5.  Combined administration of a small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis.

Authors:  Ryan T Bishop; Silvia Marino; Giovana Carrasco; Boya Li; Richard J Allen; Anna Sparatore; Penelope D Ottewell; Patrick Mollat; Andrew H Sims; Mattia Capulli; Ning Wang; Aymen I Idris
Journal:  Cancer Lett       Date:  2020-05-28       Impact factor: 8.679

6.  TNF receptor-associated factor 4 (TRAF4) is a novel binding partner of glycoprotein Ib and glycoprotein VI in human platelets.

Authors:  J F Arthur; Y Shen; E E Gardiner; L Coleman; D Murphy; D Kenny; R K Andrews; M C Berndt
Journal:  J Thromb Haemost       Date:  2011-01       Impact factor: 5.824

Review 7.  Tumor necrosis factor receptor-associated factors (TRAFs).

Authors:  J R Bradley; J S Pober
Journal:  Oncogene       Date:  2001-10-01       Impact factor: 9.867

8.  Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemia.

Authors:  Esteban Braggio; Jonathan J Keats; Xavier Leleu; Scott Van Wier; Victor H Jimenez-Zepeda; Riccardo Valdez; Roelandt F J Schop; Tammy Price-Troska; Kimberly Henderson; Antonio Sacco; Feda Azab; Philip Greipp; Morie Gertz; Suzanne Hayman; S Vincent Rajkumar; John Carpten; Marta Chesi; Michael Barrett; A Keith Stewart; Ahmet Dogan; P Leif Bergsagel; Irene M Ghobrial; Rafael Fonseca
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

9.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2.

Authors:  Sergio E Alvarez; Kuzhuvelil B Harikumar; Nitai C Hait; Jeremy Allegood; Graham M Strub; Eugene Y Kim; Michael Maceyka; Hualiang Jiang; Cheng Luo; Tomasz Kordula; Sheldon Milstien; Sarah Spiegel
Journal:  Nature       Date:  2010-06-24       Impact factor: 49.962

View more
  2 in total

1.  Silencing TRAIP suppresses cell proliferation and migration/invasion of triple negative breast cancer via RB-E2F signaling and EMT.

Authors:  Yan Zheng; Huiqing Jia; Ping Wang; Litong Liu; Zhaoxv Chen; Xiaoming Xing; Jin Wang; Xiaohua Tan; Chengqin Wang
Journal:  Cancer Gene Ther       Date:  2022-09-05       Impact factor: 5.854

2.  TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer.

Authors:  Yayun Gu; Huanyao Gao; Huan Zhang; August John; Xiujuan Zhu; Suganti Shivaram; Jia Yu; Richard M Weinshilboum; Liewei Wang
Journal:  Oncogene       Date:  2022-07-21       Impact factor: 8.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.